CommercialPrior AuthMedium impact
Velaglucerase Alfa (VPRIV®)
BCBS Tennessee·TN · Genetics, Hematology, Internal Medicine +1 more·Medical Policy
Effective date
Oct 31, 2026
We identified it
Aug 13, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new prior authorization requirement and coverage policy for Velaglucerase Alfa (VPRIV®), an enzyme replacement therapy for Gaucher disease types 1, 2, and 3. The policy requires step therapy, specialized prescriber credentials, baseline diagnostic testing, and clinical evidence of disease before initial approval; continuation therapy requires documented clinical benefit. This policy becomes effective October 31, 2026, and applies to all Tennessee members.
Action Required
Before October 31, 2026: (1) Billing team must implement prior authorization requirement in billing system for VPRIV (J3398) using the BlueCross BlueShield of Tennessee Step Therapy Guide (https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf). (2) Update encounter forms and provider workflows to require: Beta-glucocerebrosidase enzyme assay or genetic testing results, documentation of baseline clinical signs/symptoms (bone disease, splenomegaly, hepatomegaly, cytopenia), and verification that prescriber is a metabolic disease or lysosomal storage disorder specialist. (3) For continuation requests, ensure documentation of clinical benefit (improvement in liver/spleen volume, hemoglobin, or platelet count) is captured and submitted. (4) Configure system to limit dosing to 60 units/kg IV every 2 weeks. (5) Create prior auth submission checklist for providers. Providers must verify that all documentation requirements are met before submitting claims. Failure to obtain prior authorization or submit required documentation will result in claim denials.